Richard B. Bell
Providence Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard B. Bell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:51 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02274155 · Anti-OX40 Antibody in Head and Neck Cancer PatientsProvidence Health & Services · completed · Head and Neck Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 14 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Spatiotemporal molecular elucidation of radiation-induced tumor microenvironment remodeling to en-hance immunotherapy in head and neck cancerR01CA301042 · NCI · PROVIDENCE HEALTH & SERVICES - OREGON · fiscal years 2026 · $715,710 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:51 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 436 citationsRCR 41.2
- 365 citationsRCR 89.3
- Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.J Immunother Cancer · 2021174 citationsRCR 8.6
- 130 citationsRCR 6.1
- The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.Mult Scler · 200791 citationsRCR 2.2
- The effect of immunomodulatory treatment on multiple sclerosis fatigue.J Neurol Neurosurg Psychiatry · 200469 citationsRCR 2.3
- Pilot study of minocycline in relapsing-remitting multiple sclerosis.Can J Neurol Sci · 200851 citationsRCR 1.4
- 41 citationsRCR 2.1
- 28 citationsRCR 8.4
- 13 citationsRCR 3.7